The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

A new study has found that combining two weight-loss drugs, Eli Lilly's experimental drug bimagrumab and Novo Nordisk's Wegovy, which contains semaglutide, helps people lose weight while keeping ...

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

Pharmaceutical giant Eli Lilly that new preliminary research indicates its medication Zepbound helps patients lose more weight in a shorter time frame compared to Novo Nordisk's Wegovy. According ...

Another experimental Eli Lilly drug, bimagrumab, helped preserve lean muscle mass and drive greater fat loss in patients taking the popular obesity treatment Wegovy from Novo Nordisk in a mid ...

Wegovy launch in India challenges Eli Lilly's Mounjaro Analysts say Wegovy priced competitively to Mounjaro Novo faces competition from generic drugmakers Wegovy 0.25 mg, 0.5 mg and 1 mg available ...

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.

Orforglipron, which Lilly licensed from Chugai, showed strong late-stage trial results, matching the safety and efficacy of popular injectables like Novo Nordisk A/S’ (NYSE:NVO) Wegovy and ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round. Skip to content.